Lidocaine Injection and Ischemic Compression on Chronic Pelvic Pain Treatment
Lidocaine Injection and Ischemic Compression on Chronic Pelvic Pain Treatment
Our hypothesis is that with comparison of effectiveness of two most common techniques of
 treatment for myofascial pain syndrome (injection of local anesthesia and ischemic
 compression) we could choice the most adequate to treat this disease. This way we could
 decrease the expenses with medicines, examinations, consultations and the time that women
 remains without a diagnosis and treatment.
After evaluation and diagnostic confirmation, the patients will be randomized and submitted
 to the treatment with lidocaine injection or ischemic compression. Each treatment will be
 placed once a week, for four weeks. Women randomized for treatment with Ischemic compression,
 will be first subjected to transcutaneal electrostimulation(TENS), in order to receive
 analgesia on trigger point. The analgesia will be used to inhibit the painful stimulation.
 The device used for this will be the Dualpex 961, with 100 Hertz of frequency and pulse of
 250ms. The intensity will be vary according the painful threshold of each patient. The
 electrostimulation will be made for 30 minutes. The electrodes will be applied around the
 trigger point. After analgesia, the ischemic compression will be applied. This therapy
 consists in a continuous pressure on trigger point. For this we will use one algometer to get
 maximum of homogeneity on therapy. The pressure intensity will be placed by the average
 between the values gotten during three previously measurements of threshold pain in each
 patient. This therapy will be applied three times with duration of 60 seconds each with a 30
 seconds of rest between the applications. Injection of anesthesia: this therapy will be
 applied directly in trigger points with two mL of lidocaine 0.5% with needle of 22 gauges
 directly and perpendicularly in trigger point. The Evaluations for each treatment will be
 carried immediately before the randomization; In one month: immediately after the four weeks
 of treatment; - Three months: three months after the treatment; - Six months: six months
 after the treatment.
Inclusion Criteria:

 1. Women with chronic diagnosis of pelvic pain;

 2. Women in menacme;

 3. Presence of the diagnostic criteria for abdominal myofascial syndrome;

 4. Agreement with the Term of Free and Clarified Assent.

 Exclusion Criteria:

 1. Endometriosis, interstitial cystitis, syndrome of the irritable intestine or another
 illness that it justifies or it contributes for chronic pelvic pain;

 2. Endometrioma or hernia evidenced to the ultrasound of the abdominal wall.